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The selective inhibition of bacterial b-glucuroni-
dases was recently shown to alleviate drug-induced
gastrointestinal toxicity in mice, including the dam-
age caused by the widely used anticancer drug iri-
notecan. Here, we report crystal structures of repre-
sentative b-glucuronidases from the Firmicutes
Streptococcus agalactiae and Clostridium perfrin-
gens and the Proteobacterium Escherichia coli,
and the characterization of a b-glucuronidase from
the Bacteroidetes Bacteroides fragilis. While largely
similar in structure, these enzymes exhibit marked
differences in catalytic properties and propensities
for inhibition, indicating that the microbiome main-
tains functional diversity in orthologous enzymes.
Small changes in the structure of designed inhibi-
tors can induce significant conformational changes
in the b-glucuronidase active site. Finally, we estab-
lish that b-glucuronidase inhibition does not alter
the serum pharmacokinetics of irinotecan or its
metabolites in mice. Together, the data presented
advance our in vitro and in vivo understanding of
the microbial b-glucuronidases, a promising new
set of targets for controlling drug-induced gastroin-
testinal toxicity.
INTRODUCTION
It is increasingly clear that the bacteria that live on and within
the human body are involved in a range of physiological pro-
cesses. Changes to the microbiota have been found to accom-
pany several disease states, including diabetes, atherosclerosis,
obesity, malnutrition, cancer, gastrointestinal (GI) inflammatory1238 Chemistry & Biology 22, 1238–1249, September 17, 2015 ª201disorders, and neurological diseases (Cho et al., 2012; Hsiao
et al., 2013; Methe´ et al., 2012; The Human Microbiome Project
Consortium, 2012; Morgan et al., 2012; Nicholson et al., 2012;
Plottel and Blaser, 2011; Smith et al., 2013; Turnbaugh et al.,
2006; Wang et al., 2011). Ongoing chemical interactions
between mammalian tissues and their colonizing microbiota
appear to play important roles in the symbiosis that sustains
both domains of life (Mani et al., 2014; Redinbo, 2014). A key
player in this interplay is glucuronic acid. This small sugar is con-
jugated, typically in the liver, to drugs and endobiotics marked
for excretion, commonly via the bile duct to the GI tract (Holmes
et al., 2011). In their glucuronidated states, most chemicals are
inactive. The GI microbiota, however, contain b-glucuronidase
enzymes that scavenge this sugar as a source of carbon.
Removal of the glucuronide moiety produces aglycones that
are often still eliminated, although they can be reabsorbed into
the plasma and return to the liver as part of normal enterohepatic
recycling. Importantly, reactivated aglycones can also be highly
toxic to the GI tissues, and, as outlined below, there is evidence
that such compounds can lead to serious side effects in human
patients (Wallace and Redinbo, 2013).
Irinotecan (CPT-11) is a potent anticancer drug used to treat
solid tumors and other malignancies (Cunningham et al., 1998;
Douillard et al., 2000; Hurwitz et al., 2004). It is an essential
component of FOLFIRI (where IRI indicates irinotecan), which
is widely used for late-stage colorectal cancer (Kelly and
Goldberg, 2005), and FOLFIRINOX, which was recently recom-
mended as the first-line regimen for pancreatic cancer (Conroy
et al., 2011). Irinotecan causes severe diarrhea in a significant
fraction of patients, commonly leading to dose reductions or
treatment termination (Chabot, 1996; Ma and McLeod, 2003;
Mathijssen et al., 2001). The irinotecan prodrug is activated
to the human topoisomerase I poison SN-38 in patients; this
active metabolite is further processed by UDP-glucuronosyl-
transferases to become the inactivated glucuronide conjugate
SN-38-G, which is sent to the GI tract for elimination (Chabot,
1996;Ma andMcLeod, 2003) (Figure S1). In theGI tract, bacterial5 Elsevier Ltd All rights reserved
b-glucuronidase enzymes remove the glucuronic acid and
reactivate the topoisomerase I poison SN-38, which causes GI
damage and the diarrhea that is dose-limiting for irinotecan
(Dranitsaris et al., 2005; Gupta et al., 1994; Rothenberg et al.,
2001; Stein et al., 2010) (Figure S1). According to the Food
and Drug Administration package insert for irinotecan, up to
88% of patients experience diarrhea and 31% show grade 3–4
diarrhea, which requires significant medical intervention. Thus,
the alleviation of the chemotherapy-induced diarrhea caused
by irinotecan is an unmet medical need.
A low-potency b-glucuronidase inhibitor showed promise in
2004 in reducing the GI toxicity associated with irinotecan in
rats (Fittkau et al., 2004). We reported more potent (<mM) and
novel inhibitors of bacterial b-glucuronidases in 2010, and
showed that they significantly reduced the GI damage caused
by irinotecan in mice (Wallace et al., 2010). We showed that
these inhibitors were non-toxic to both bacterial and mammalian
cells, and demonstrated using crystal structures and other data
that the inhibitors were selective for the bacterial b-glucuroni-
dases by more than 1,000-fold over the human enzyme ortholog
(Roberts et al., 2013; Wallace et al., 2010). We pinpointed the
basis of the selectivity to a loop present in bacterial b-glucu-
ronidases that is missing from the human enzyme ortholog; the
inhibitors bind to this loop, making them ineffective against
mammalian b-glucuronidases (Wallace et al., 2010).
We have since demonstrated that the same approach can be
applied to the non-steroidal anti-inflammatory drugs (NSAIDs),
some of the world’s most widely used therapeutics (Brune
and Hinz, 2004). NSAIDs cause serious lower GI ulcers that
have been less appreciated than the gastric side effects more
commonly associated with these compounds (Laine et al.,
2003; Lanas, 2010). Seventy percent of long-term NSAID users
have chronic lower GI inflammation, increased permeability,
and malabsorption, 40% have ulcers, and 30% suffer from GI
bleeding and anemia (Lanas and Sopena, 2009). Like SN-38,
NSAIDs are inactivated by glucuronidation and reactivated
in the GI tract back to the parent drugs, which can then cause
significant enteropathy largely in the small intestine via mecha-
nisms that are not completely understood (Boelsterli et al.,
2012). In mouse models of GI toxicity caused by the NSAIDs
diclofenac, ketoprofen, or indomethacin, we showed that oral
dosing of bacterial b-glucuronidase inhibitors significantly
reduced the numbers of small-intestinal ulcers observed (LoGui-
dice et al., 2012; Mani et al., 2014; Saitta et al., 2014). We also
demonstrated that inhibition of bacterial b-glucuronidases did
not alter serum levels of diclofenac in mice (LoGuidice et al.,
2012). Thus, modulating the activity of enzymes encoded by
the symbiotic bacteria in the mammalian GI tract can improve
tolerance to two classes of drugs, irinotecan and NSAIDs.
To date, these investigations have focused on the b-glucuron-
idase from Escherichia coli (Roberts et al., 2013; Wallace et al.,
2010). While the Proteobacteria, including E. coli, are present
in themammalian GI tract, other phyla aremore significantly pre-
dominant, particularly the Firmicutes and the Bacteroidetes (The
Human Microbiome Project Consortium, 2012). Thus, to expand
our understanding of the structure, function, and in vitro inhibi-
tion of bacterial b-glucuronidases, we cloned, overexpressed,
purified, characterized, and determined the crystal structures
of representative b-glucuronidases from the Firmicutes speciesChemistry & Biology 22, 1238–124Streptococcus agalactiae and Clostridium perfringens, each of
which is present in the human GI tract. We also characterized
a b-glucuronidase from Bacteroides fragilis, a GI microbe repre-
sentative of the Bacteroidetes phylum. We demonstrate that
a small chemical change to an inhibitor affects its efficacy,
pharmacokinetics, and binding to a bacterial b-glucuronidase.
Finally, we show that the inhibition of GI bacterial b-glucuroni-
dases in mice does not alter the serum levels of irinotecan or
its key metabolites SN-38 and SN-38-G. Together, these data
extend our understanding of the microbial b-glucuronidases,
which might serve as targets to reduce the toxicity and improve
the efficacy of irinotecan and NSAIDs.
RESULTS
Crystal Structures of Firmicutes b-Glucuronidases
To advance our understanding of the structure and function
of bacterial b-glucuronidase, the b-glucuronidases from two Fir-
micutes species associated with the mammalian GI microbiota,
C. perfringens (CpGUS) and S. agalactiae (SaGUS), were cloned,
overexpressed, and purified, and the structures of each were
determined to 2.3 A˚ resolution (Figure 1A and Table S1). The
structure of the b-glucuronidase from the Proteobacterial
species E. coli (EcGUS), also present in the mammalian GI tract,
was also determined in complex with a novel inhibitor, R1, to
2.4 A˚ resolution (Figure 1A and Table S1). The structures of the
two Firmicutes enzymes are the first from this phylum. The
CpGUS structure (PDB: 4JKM) shares 0.77 A˚ root-mean-square
deviation (rmsd) over 453 equivalent Ca positions with the struc-
ture of apo EcGUS (PDB: 3K46) and 48% sequence identity
(Wallace et al., 2010). The P21212 (PDB: 4JKL) and I222 (PDB:
4JKK) SaGUS structures share 0.91 and 0.93 A˚ rmsd, respec-
tively, over 432 and 431 equivalent Ca positions with the struc-
ture of E. coli b-glucuronidase. SaGUS and EcGUS share 42%
sequence identity. The two Firmicutes enzymes, CpGUS and
SaGUS, share 0.55 A˚ (P21212) and 0.56 A˚ (I222) rmsd over 440
and 436 equivalent Ca positions and 53% sequence identity.
The two SaGUS structures share 0.22 A˚ rmsd over 527 equiva-
lent Ca positions. The three microbial enzymes, CpGUS, SaGUS
(P21212), and EcGUS, share 0.63, 0.85, and 0.72 A˚ rmsd, respec-
tively, with the structure of human b-glucuronidase (HsGUS,
PDB: 3HN3) (Jain et al., 1996) (Hassan et al., 2013) over 457,
424, and 441 equivalent Ca positions, and 46%, 38%, and
48% sequence identities, respectively. Thus, the Firmicutes
enzymes reported here exhibit overall structures similar to the
EcGUS and HsGUS structures reported previously, and all are
members of the glycosyl hydrolase 2 (GH2) family of enzymes.
b-Glucuronidase N-K Fingerprint
Using these b-glucuronidase crystal structures as a guide, we
next sought to define functionally relevant sequence motifs.
b-Glucuronidases align ether-linked glucuronides for hydrolysis
using hydrophobic, hydrogen bonding, and electrostatic interac-
tions with the glucuronic acid sugar moiety (Figure 1B). The
asparagine and lysine residues that contact the carboxylic acid
group unique to glucuronic acid relative to galactose are partic-
ularly critical (Figure 1B). In an alignment of b-glucuronidase
sequences obtained from the NCBI, the asparagine and lysine
(N-K) residues that contact the carboxylic acid are completely9, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1239
Figure 1. Firmicutes and Bacteroidetes b-Glucuronidase Crystal Structures
(A) Novel crystal structures of bacterial b-glucuronidases, two from the Firmicutes phylum, Clostridium perfringens (yellow; CpGUS) and Streptococcus
agalactiae (magenta; SaGUS), and one from the Proteobacteria phylum, Escherichia coli (EcGUS) in complex with designed Inhibitor R1 (blue).
(B) Superposition of the active sites the b-glucuronidases from C. perfringens (yellow) and S. agalactiae (magenta) on that of E. coli b-glucuronidase (green) in
complex with the glucuronic acid mimic glucaro-d-lactam, showing the binding of the ligand’s carboxylate moiety (left) and indicating that the proximity of the
conserved tyrosine indicated (YI468/464) favors the alignment of a b linkage (right) for catalysis. The labels for the two catalytic glutamic acid residues of each
enzyme are boxed.
(C) The Asn (N) and Lys (K) residues create the N-K loop conserved in b-glucuronidases but not in the putative b-galactosidase 3DEC from Bacteroides
thetaiotaomicron (Bt3DEC, purple). b-Glucuronidases listed include those presented here (e.g., CpGUS, SaGUS), as well as those from mammalian (Homo
sapiens, HsGUS), Archaeal (ArchIa), Thermatogae (ThermTn), and other sources. The enzymes for which a crystal structure is available are underlined. ArchIa,
Archaea Ignisphaera aggregans, WP_013302863; TherTn, Thermotogae Thermotoga naphthophila, ADA67771; BactNk, Bacteroidetes Niastella koreensis,
AEV98753; H11G11, 745-residue protein from uncultured bacterium.
(D) The glycosyl hydrolase from B. thetaiotaomicron (PDB: 3DEC; Bt3DEC; left) lacks the Lys and Asn residues necessary to bind a glucuronic acid sugar for
catalysis; thus, this enzyme appears to be a b-galactosidase. By contrast, the glycosyl hydrolase fromBacteroides fragilis (PDB: 3CMG;Bf3CMG; right) maintains
the active-site residues capable of glucuronic acid binding. The labels for the two catalytic glutamic acid residues of each enzyme are boxed.conserved, including in the three structures reported here
(CpGUS, SaGUS, and EcGUS), as well as in the HsGUS enzyme
(Figure 1C). This motif is present in more distantly related b-glu-
curonidases from Archaeal and Thermotoga sources, as well as
Bacteroides species and a gene obtained from uncultured
sample whose gene product, H11G11, was demonstrated to
have b-glucuronidase activity (Gloux et al., 2011) (Figure 1C).
In addition to N-K, a tyrosine residue (Y468 or Y464 in Figure 1B)
located 4 A˚ from the glucuronic acid binding site appears to
ensure by steric occlusion that only b-linked substrates are
processed by the two catalytic glutamic acid residues of b-glu-
curonidases; an a linkage would clash with the aromatic ring at
this position (Figure 1B). We examined the N-K motif region in1240 Chemistry & Biology 22, 1238–1249, September 17, 2015 ª201the structures of GH2 family enzymes from B. fragilis (RCSB:
3CMG) and Bacteroides thetaiotaomicron (RCSB: 3DEC) that
were deposited in the Research Collaboratory for Structural
Bioinformatics in 2012. As shown in Figures 1C and 1D, 3CMG
maintains the N-K motif associated b-glucuronidases, while
the 3DEC glycosyl hydrolase lacks the N-K motif and instead
contains Cys and Asn residues in these locations (Figures 1C
and 1D). Thus, 3CMG would be expected to be a b-glucuroni-
dase, and 3DEC, because it lacks the N-K motif, would be
expected to act on distinct substrates, perhaps as a b-galac-
tosidase. As shown below, 3CMG is a b-glucuronidase. Thus,
the N-K sequence motif can be employed as a fingerprint to
identify b-glucuronidases from the large GH2 family of proteins.5 Elsevier Ltd All rights reserved
Figure 2. Bacterial- and Mammalian-Type b-Glucuronidases Exhibit Distinct Bacterial and M Loops
(A) The three novel bacterial b-glucuronidase structures presented here (yellow, magenta, blue) superimposed on the structure of human b-glucuronidase (gray)
reveals both the lack of a bacterial loop in the mammalian enzyme, as well as the lack of an M loop in the mammalian enzyme (inset).
(B) The bacterial loop, boxed, is maintained in the L-GUS enzymes, including those from several fungi (red), but is missing from the no-loop b-glucuronidases
(NL-GUS) and the B. thetaiotaomicron (Bt3DEC) b-galactosidase. The enzymes for which a crystal structure is available are underlined. PROT, Proteobacteria
Vibrio harveyi, WP_005434141; ACTIN, Actinobacteria Corynebacterium massiliense, WP_022863751; FUNGI, Eukaryota Aspergillus niger, CAK36851; ArchIa,
Archaea Ignisphaera aggregans, WP_013302863; TherTn, Thermotogae Thermotoga naphthophila, ADA67771; DICTY, Dictyoglomi Dictyoglomus turgidum,
ACK42813; BactNk, BacteroidetesNiastella koreensis, AEV98753; ACIDO, Acidobacteriua Terriglobus roseus, WP_01478374; H11G11, 745-residue protein from
uncultured bacterium.
(C) A hydrophobic M loop is missing from several no-loop b-glucuronidases (NL-GUS), such asHsGUS and Bf3CMG, but is present in others, and is conserved in
the bacterial loop-containing b-glucuronidases (L-GUS). The enzymes for which a crystal structure is available are underlined.
(D) Active-site superposition of EcGUS-Inh2 complex (dark blue) on BfGUS (3CMG; light blue) showing the catalytic residues and bacterial loop of EcGUS. The
384–393 region of BfGUS, which is significantly shorter than the bacterial loop of EcGUS (357–371), would clash with the binding site of compounds such as
Inhibitor 2. In addition, in the EcGUS tetramer, loops from different monomers (e.g., 1 and 2 shown) participate in binding contacts with Inhibitor 2. BfGUS does
not form an analogous tetramer and cannot form a similar inhibitor binding site.Bacterial and M Loops of Microbial b-Glucuronidases
The bacterial b-glucuronidases presented here contain two
additional motifs unique relative to the human b-glucuronidase
structure. First, many contain a ‘‘bacterial loop’’ that folds
over the active sites of microbial enzymes, which processes
small substrates (Wallace et al., 2010; Figure 2A). By contrast,
human b-glucuronidase, which processes larger glucosamino-
glycan-glucuronide substrates, lacks this loop. In the CpGUS
and SaGUS structures presented here, this loop is 14 and 13
residues in length, respectively, is visualized in its entirety in
CpGUS, and is partially ordered in SaGUS and in the EcGUS-Chemistry & Biology 22, 1238–124R1 complex (where it is 17 residues in length; Figures 2A and
S2). The EcGUS-Inh2 structure reported previously contained
a fully ordered loop, and a comparison of this loop and the or-
dered loop from CpGUS presented here demonstrates that this
region is structurally flexible (Figures 2A and S2). Bacterial loops
are also divergent in sequence, sharing only 11%–36% identity
between theEcGUS,CpGUS, andSaGUS. InHsGUS, this region
is replaced by a single residue, P415 (Figure 2A).
Sequence analysis of bacterial loops in a set of microbial
b-glucuronidase enzymes from the NCBI database reveals
that some of the enzymes contain the loop and some do not9, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1241
Table 1. Catalytic Activity of b-Glucuronidases
Enzyme kcat (s
1) KM (mM) kcat/KM (s
1 mM1)
EcGUS 120 ± 12 0.13 ± 0.01 920
SaGUS 80 ± 2 0.36 ± 0.03 224
CpGUS 2.6 ± 0.6 1.1 ± 0.2 2.4
BfGUS 18 ± 1 1.9 ± 0.3 9.5
Data are presented as the average over >3 experiments ± SEM for Es-
cherichia coli (EcGUS), Clostridium perfringens (CpGUS), Streptococcus
agalactiae (SaGUS), and Bacteroides fragilis (BfGUS) b-glucuronidases.
kcat, catalytic rate; KM, Michaelis constant; kcat/KM, catalytic efficiency.(Figure 2B). Phyla that encode a b-glucuronidase with an intact
bacterial loop include Firmicutes, Proteobacteria, and Actino-
bacteria, aswell as representatives from the fungi such asAsper-
gillus niger (Figure 2B). Phyla with b-glucuronidases lacking
the bacterial loop include the Bacteroidetes, Dictyoglomi, and
Acidobacteria. The b-glucuronidase from B. fragilis, 3CMG,
lacks the bacterial loop. Representative b-glucuronidases in
Archaea, such as Ignisphaera aggregans, and in Thermatogae,
such as Thermotoga naphthophila (Figure 2B), also lack the bac-
terial loop. All sequences in this alignment contain the conserved
catalytic b-glucuronidase residues outlined in Figure 1B, as well
as the N-Kmotif (see Figure 1C), and are therefore considered to
be representative of the range of b-glucuronidases present in
sequenced microbiota.
Second, a minor structural feature unique to the microbial
b-glucuronidases is the presence of a dipeptide within the active
site composed of Leu-Met in Cp and SaGUS, and Met-Phe in
EcGUS (Figure 2A). This motif is missing from HsGUS but is pre-
sent in most, but not all, L-GUS and NL-GUS enzymes from
NCBI sequences (Figure 2C). Due to the prevalence of Met res-
idues in this short region, we refer to it as the M loop. In the Cp,
Sa, andEcGUS structures, this region is located7.5 A˚ from cat-
alytic residue E413 and contacts bound inhibitors, suggesting
that it may play a role in substrate binding and catalytic function.
Based on these sequence and structural considerations, we
propose that microbial b-glucuronidases can be divided into
two major groups: the L-GUS enzymes (loop-b-glucuronidases),
resembling the initially characterized bacterial enzymes and con-
taining a bacterial loop, and the NL-GUS (no-loop) enzymes,
which, as shown here, maintain all major features of b-glucuron-
idases but lack the bacterial loop. As outlined in more detail
below, these groupings provide a useful tool in understanding
the b-glucuronidases of known sequence.
Microbial b-Glucuronidases Are Distinct in Catalytic
Activity and Inhibition
We compared the kcat, KM, and catalytic efficiencies (kcat/KM)
of the microbial b-glucuronidases examined here using the
standard p-nitrophenyl glucuronide b-glucuronidase assay sub-
strate. The B. fragilis b-glucuronidase 3CMG, a representative
GUS from the Bacteroidetes phylum, was overexpressed in
E.coliandpurified for kinetic characterization.Markeddifferences
in all three parameters were observed (Table 1), with EcGUS ex-
hibiting the best activity (kcat = 120 s
1, KM = 0.13 mM, and kcat/
KM = 920 s
1 mM1), SaGUS showing moderate activity (kcat =
80 s1, KM = 0.36mM, and kcat/KM = 224 s
1 mM1), andCpGUS1242 Chemistry & Biology 22, 1238–1249, September 17, 2015 ª201demonstrating the slowest kcat (2.6 s
1), theweakestKM (1.1mM),
and the least catalytic efficiency kcat/KM (2.4 s
1 mM1). The
B. fragilis b-glucuronidase 3CMG (BfGUS) exhibited a poor KM
of only 1.9 mM, but a kcat (18 s
1) roughly three times higher
than CpGUS, and thus showed a catalytic efficiency nearly five
times higher than CpGUS. These data establish for the first time
that BfGUS is a b-glucuronidase, and that the four enzymes
from three representative GI bacterial phyla exhibit a range of
catalytic efficiencies with this standard b-glucuronidase assay
substrate.
We also examined the ability of the Proteobacteria and Firmi-
cutes enzymes to be inhibited by Inhibitors 1–8 previously identi-
fied bya10,000-compoundhigh-throughput screenusingEcGUS
(Roberts et al., 2013;Wallace et al., 2010; Figure S3). These com-
pounds all inhibit EcGUS, with allKi values below 2 mM (Table S2).
Two novel compounds, R1 and R3, which are designed analogs
of Inhibitor 1 and are shown in Figure 3A, were also synthesized
and exhibited Ki values of 1.9 and 0.61 mM, respectively, toward
EcGUS, and EC50 values of 4.5 and 3.1 mM, respectively, in
culturedE. coli cells (Tables S2 andS3). In previous studies, Inhib-
itor 1 demonstrated an EC50 of 17 nM for cultured E. coli.
Interestingly, all ten compounds exhibit markedly differential
effects toward the two novel microbial b-glucuronidases,
CpGUS and SaGUS, presented here (Table S2). For example,
Inhibitors R1, R3, 7, and 8 show no inhibition of the Cp and Sa
b-glucuronidases, but are 0.61–2 mM inhibitors of the E. coli
enzyme. Similarly, Inhibitors 2, 3, and 6 are 0.2–0.7 mM inhibitors
ofEcGUS, but are up to 16-fold weaker (e.g., 11 mM for Inhibitor 3
toward Sa versus 0.68 mM for Ec) toward the Firmicute enzymes
from SaGUS and CpGUS. Thus, distinct chemotypes can exert
ortholog-specific effects on the activities of purified microbial
b-glucuronidases.
We next examined whether a no-loop (NL) b-glucuronidase
from the Bacteroidetes phylum can be inhibited by the com-
pounds we have in hand. We found that BfGUS is not subject
to inhibition by Inhibitors 1–8 at up to 100-mM inhibitor concen-
trations (Table S2). This result is reminiscent of the data collected
previously on the mammalian GUS from bovine, which was also
not subject to inhibition by Inhibitors 1–8 (Roberts et al., 2013;
Wallace et al., 2010). Both bovine GUS and BfGUS are NL-GUS
enzymes, in contrast to the Firmicutes and Proteobacteria en-
zymes, which are L-GUS enzymeswith bacterial loops. Superim-
posing the structure of EcGUS in complex with Inhibitor 2 with
BfGUS from crystal structure 3CMG reveals that the residues
384–393 of BfGUS would clash with the inhibitor binding site
(Figure 2D). Furthermore, while both enzymes are shown here
to form tetramers by multi-angle light scattering in solution, by
structural analysis the tetramers they form are distinct (Fig-
ure S4). Indeed, BfGUS fails to maintain the dimer contacts
shown previously for EcGUS to be involved in inhibitor binding
(Wallace et al., 2010) (Figure 2D). Taken together, these observa-
tions provide molecular explanations for the lack of inhibition
of BfGUS by Inhibitors 1–8. We conclude the NL-GUS enzymes
will not be subject to inhibition by the reagents that potently
inhibit the L-GUS enzymes.
Reducing Serum Exposure of Inhibitors
We next hypothesized that inhibitors intended to target en-
zymes in the GI lumen would be improved by limiting their serum5 Elsevier Ltd All rights reserved
Figure 3. Novel Bacterial b-Glucuronidase Inhibitors
(A) Inhibitors R1 and R3 were designed, based on Inhibitor 1 (gray), to reduce relative GI absorption. Inhibitor 2, for which a crystal structure bound to E. coli
b-glucuronidase is available, is also shown (gray).
(B) Inhibitor R1 bound to the active site of E. coli b-glucuronidase, making contacts with the bacterial loop, as well as two active-site tyrosines, 469 and 472. The
catalytic residue E413 is also shown, as are the b-glucuronidase fingerprint residues N566 and K568.
(C) Binding of Inhibitor 2 to the active site of E. coli b-glucuronidase (Wallace et al., 2010), making distinct contacts, relative to Inhibitor R1, with the bacterial loop
and one active-site tyrosine, 472.
(D) Superposition of the active sites of E. coli b-glucuronidase bound to Inhibitors R1 (blue) and 2 (green) but with the ligands removed. The relative shifts in five
active-site residues are shown, including a 15-A˚ movement of Y469 and a shift in the positions of the b-glucuronidase fingerprint residues N566 and K568.exposure. We have reported previously that Inhibitor 1 exhibits
21% oral bioavailability (F) in mice, but that increases to 99%
when the animals are given the pan-cytochrome P450 inhibitor
ABT (LoGuidice et al., 2012). This suggests that Inhibitor 1 is
absorbed from the GI tract and is subject to metabolism by
P450 enzymes. Thus, we sought to reduce the serum exposure
of Inhibitor 1 by creating two novel analogs, R1 and R3 (Figures
3A, S5, and S6). The O-ethyl group from Inhibitor 1, expected
from crystal structural analysis to accommodate derivatization,
was replaced with a hydroxyl (R1) or morpholine (R3) group,
each hypothesized to reduce GI absorption. As noted above,
inhibitors R1 and R3 are 0.6–2 mM inhibitors of EcGUS, but do
not inhibit SaGUS and CpGUS at up to 100 mM. We performed
preliminary pharmacokinetic (PK) studies on mice treated orally
with Inhibitor 1 and Inhibitors R1 and R3 to determine plasma
levels of these compounds over 24 hr, with or without the cyto-Chemistry & Biology 22, 1238–124chrome P450 inhibitor ABT. We found that the R1 compound
exhibited significantly reduced oral bioavailability (%F) alone or
with ABT relative to Inhibitor 1 or R3 (Table 2). Inhibitor R1 also
showed poor plasma exposure, as measured by maximum con-
centration and area under the curve, relative to Inhibitors 1 and
R3. Thus, R1 is either metabolized quickly or remains in the GI
tract when given orally to mice. The ability of Inhibitor R1 to alle-
viate CPT-11-induced GI damage is examined below.
E. coli b-Glucuronidase-Inhibitor R1 Complex Crystal
Structure
Wedetermined the 2.4-A˚ resolution crystal structure ofEcGUS in
complex with Inhibitor R1. This complex revealed a surprising
level of structural variability in the active-site and bacterial-loop
regions of this microbial b-glucuronidase. Inhibitor R1 was found
to bind in a unique manner to EcGUS when compared with its9, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1243
Table 2. Oral Bioavailability of b-Glucuronidase Inhibitors
Tmax (hr) Cmax (ng/ml) AUC (ng/ml/hr) %F
Inh-1 0.5 510 ± 200 960 21
Inh-1 + ABT 4.0 740 ± 20 4,900 99
R1 0.3 13 ± 0.4 24 4
R1 + ABT 0.3 27 ± 20 75 12
R3 0.3 82 ± 10 140 6
R3 + ABT 1.0 780 ± 200 2,800 100
Oral bioavailability (F) with and without treatment with the pan-cyto-
chrome P450 inhibitor ABT. Tmax, maximum time; Cmax, maximum con-
centration; AUC, area under the curve.close chemical homolog, Inhibitor 2 (Wallace et al., 2010). Inhib-
itor R1 forms a hydrogen bond between catalytic residue E413
and this compound’s phenyl ring hydroxyl (Figure 3B). In
contrast, Inhibitor 2 forms a hydrogen bond between its ethoxy
group and E413 (Figure 3C), similar to that observed in the
EcGUS-Inhibitor 3 complex (Wallace et al., 2010). Inhibitors 2
and R1 are rotated 120 about the horizontal axis with respect
to one another in the EcGUS active site, as shown in Figures 3B
and 3C. We observed a significant conformational change asso-
ciated with Inhibitor R1 binding to EcGUS. N566 and K568 of
the N-K loop, and tyrosines 468, 469, and 472 all shift in posi-
tion from 2.8 to 15 A˚ relative to the Inhibitor 2 bound structure
(Figure 3D).
These observations define a mobile Y loop within the active
site of microbial b-glucuronidases (Figure 4A). As shown in Fig-
ures 3D and 4B, Y468, Y469, and Y472 in the EcGUS-R1 com-
plex shift in position by 5.5, 9.8, and 15 A˚, respectively, relative
to their locations in the Inhibitor 2-EcGUS complex. These three
tyrosines are conserved in the sequences of the CpGUS and
SaGUS enzymes examined here (Figure 4A), and can be labeled
as YI (Y468, Y468, and Y464 in Ec, Cp, and Sa, respectively), YII
(Y469, Y469, and Y465), and YIII (Y472, Y472, and Y468). The Y
loop is capable of adopting two different positions in the crystal
structures of microbial b-glucuronidases resolved to date, as
noted previously (Wallace et al., 2010) and extended here. The
Y-loop residues in the EcGUS-R1 complex are positioned nearly
identically to that observed in the apo structure of EcGUS
reported previously, and can be considered to be ‘‘inactive’’
because the position of YI sterically blocks the Lys in the N-K
loop from forming a salt bridge with the carboxylate unique to
glucuronic acid (Figure 4C). The Y-loop residues in the EcGUS-
Inhibitor 2 and 3 structures (Wallace et al., 2010), by contrast,
are aligned well with those in the CpGUS and SaGUS structures
reported here, and the Lys of the N-K loop is positioned to
contact a bound glucuronic acid sugar (Figure 4D; see also
Figure 1B). Taken together, these data highlight the structural
plasticity present in the active sites of GUS enzymes, particularly
in the bacterial-loop and Y-loop regions, and indicate that these
shifts can affect the position of other regions of the enzyme, such
as the N-K loop.
Irinotecan Toxicity and Pharmacokinetics in Mice
Finally, we sought to determine how inhibition of microbial
b-glucuronidase activity would affect irinotecan pharmacoki-
netics and GI damage in mice. First, we examined Inhibitor1244 Chemistry & Biology 22, 1238–1249, September 17, 2015 ª201R1 for its ability to alleviate irinotecan (CPT-11)-induced diar-
rhea in mice. Without inhibitor, mice (n = 9 per group) that
receive 50 mg/kg CPT-11 intraperitoneally (i.p.) develop bloody
diarrhea after 8–10 days, with 25% of treated mice showing
this acute side effect at day 8, 60% at day 9, and 100% at
day 10 (Figure 5A). Inhibitors 1 and R1 were provided to the
same number of mice twice daily by oral gavage at 10 mg per
dose, for a total of 20 mg per day. As a positive control, the pre-
viously described Inhibitor 1 was found to reduce the number
of mice with this side effect to 20% at day 9 and 40% at
day 10. Inhibitor R1, which demonstrates 10-fold reduced
in vitro inhibition of EcGUS and no inhibition of the Firmicutes
enzymes (Table S2), showed reduced alleviation of CPT-11-
induced diarrhea, to 20% of mice at day 8, 40% at day 9,
and 60% at day 10 (Figure 5A). Thus, while Inhibitor R1 showed
a potentially beneficial lack of serum exposure in mice (Table 2),
it is deficient relative to Inhibitor 1 in its alleviation of CPT-11-
induced injury.
Second, we examined the potential impact of Inhibitor 1 on
the serum levels of CPT-11 and its key metabolites SN-38 and
SN-38-G in mice. To date, it has remained unclear whether the
reabsorption of the SN-38 created by GI microbial b-glucuroni-
dases plays a role in circulating levels of this active metabolite
of CPT-11. Using the same dosing scheme as above, plasma
levels of CPT-11, SN-38, and SN-38-G were determined using
mass spectrometry. As shown in Figures 5B and Table S4, the
presence of Inhibitor 1 appears not to alter significantly the levels
of CPT-11, SN-38, and SN-38-G. These data support the conclu-
sion that inhibiting the reactivation of SN-38 from SN-38-G in the
GI tract would not reduce the levels of SN-38 capable of reaching
tumors via the serum.
DISCUSSION
Firmicutes and Bacteroidetes are the predominant microbial
phyla in themammalian GI tract (The HumanMicrobiome Project
Consortium, 2012); here, we examine representative b-glucuron-
idases from each to advance our understanding of the structure
and function of these enzymes, which are involved in drug-
induced GI toxicity and its alleviation (LoGuidice et al., 2012;
Mani et al., 2014; Roberts et al., 2013; Saitta et al., 2014; Wallace
et al., 2010). We find that purified b-glucuronidases from the
Firmicutes, Proteobacteria, and Bacteroidetes phyla exhibit
10-, 50-, and 100-fold differences with respect to one another
in substrate binding, reaction rate, and catalytic efficiency,
respectively (Table 1). Furthermore, we find that some are
amenable to inhibition while others are not inhibited by a range
of chemotypes (Table S2). These observations support the
conclusion that the GI microbiome maintains an array of enzyme
orthologs capable of scavenging glucuronic acid from a range of
chemically distinct substrates. Diverse endobiotic, food, and
xenobiotic glucuronides are expected to be regularly delivered
to the GI tract, and thus the microbial species therein are poised
to utilize these diverse sources of carbon. It will be of interest to
determine in future studies whether specific symbiotic bacteria
are responsible for reactivating specific drug- or endobiotic glu-
curonides. For example, a particular set of bacteria may be most
efficient at reactivating SN-38G while another efficiently pro-
cesses NSAID glucuronides. Such knowledge may enable the5 Elsevier Ltd All rights reserved
Figure 4. Bacterial b-Glucuronidases Exhibit Dynamic Y Loops
(A) The first (YI), second (YII), and third (YIII) tyrosines of the Y loop are conserved in both the bacterial- and mammalian-type b-glucuronidases. See the legend of
Figure 2 for labels.
(B) Superposition of the active sites of C. perfringens (yellow; CpGUS), S. agalactiae (magenta; SaGUS), and the E. coli Inhibitor R1 complex (blue; EcGUS-R1)
showing the dramatic shifts in position in tyrosine residues YI (Tyr 464 or 468), YII (Tyr 465 or 469), and YIII (Tyr 468 or 472) of the Y loop, and in the b-glucuronidase
fingerprint sequence of theN-K loop. The view is rotated approximately 45 about the horizontal axis relative to Figure 3, and the two catalytic Glu residues of each
enzyme are shown.
(C) The E. coli b-glucuronidase Inhibitor R1 complex (blue; EcGUS-R1) superimposes well on the active site of the unliganded structure of the enzyme (purple;
EcGUS apo) (Wallace et al., 2010).
(D) In contrast to (C), the unliganded C. perfringens (yellow; CpGUS) and S. agalactiae (magenta; SaGUS) b-glucuronidase structures superimpose well in this
region with the liganded E. coli b-glucuronidase Inhibitor 2 complex (green; EcGUS-Inh2) (Wallace et al., 2010).development of more tailored inhibitors for specific drug-
induced GI enteropathies.
At the structure-function level, we find that b-glucuronidases
exhibit conformational flexibility within their active sites, and
can adopt active and inactive states (Figures 3 and 4). We
also demonstrate that b-glucuronidases contain Asn and Lys
residues (an N-K motif) in their active site that coordinates
the carboxylate group unique to glucuronic acid relative to
galactose (Figure 1). This observation was anticipated by the
work of Matsumura and Ellington (2001), who evolved glucu-
ronidase activity from galactosidase enzymes and noted that
the N-K motif was essential. The aromatic-rich Y motif is also
conserved across glucuronidases of known sequence; these
tyrosines make contact with substrate and inhibitor ligandsChemistry & Biology 22, 1238–124and, in the case of EcGUS, are observed to adopt distinct
conformations depending on the nature of the ligand bound.
Thus, we propose that the N-K and Y motifs should join the
catalytic glutamic acid residues as structural features consid-
ered essential for b-glucuronidase activity. A B. fragilis glycosyl
hydrolase, the structure of which was reported in 2008
(RCSB: 3CMG), was annotated at that time as a b-galactosi-
dase, an understandable conclusion given its significant simi-
larity to b-galactosidases from other Bacteroides species
(e.g., 3DEC, 3BGA). However, unlike such related b-galactosi-
dases, 3CMG contains an N-K motif, and here we confirm in
in vitro assays that it is a b-glucuronidase. This result highlights
the potential for using the N-K motif to identify the b-glucuron-
idases present in the GI microbiome.9, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1245
Figure 5. Microbial b-Glucuronidase Inhibitors in Mice Treated with CPT-11
(A) CPT-11 (irinotecan) produced delayed diarrhea in 25%, 60%, and 100% of mice in 8, 9, and 10 days, respectively. Oral delivery of Inhibitor R1, a 1.9-mM
inhibitor of E. coli b-glucuronidase, reduces the number of mice that experience diarrhea at days 9 and 10 to 40% and 60%, respectively, but is less effective than
Inhibitor 1, a 0.16-mM inhibitor, on which it was based. N = 9 mice per group.
(B) The circulating plasma levels of CPT-11, its active metabolite SN-38, or its inactive glucuronide conjugate SN-38-G are unaffected by the oral delivery of the
microbial b-glucuronidase Inhibitor 1 (Inh1).We conducted a phylogenetic analysis of microbial and
mammalian b-glucuronidase sequences from a taxonomically
diverse group of cultured organisms. The resulting phylogenetic
tree of b-glucuronidases from organisms in all three kingdoms in-
dicates the tremendous diversity of b-glucuronidase sequences
and the broad distribution of this gene across the tree of life (Fig-
ure S7). This analysis further supports the conclusion that the
b-glucuronidases can be effectively divided into those that main-
tain a loop of their active sites (L-GUS) and those that do not (NL-
GUS). The majority of loop-positive bacteria are allocated into
two phyla, Firmicutes and Actinobacteria, both prominent in
the human gut. Sequenced representatives of the Bacteroidetes,
also a prominent GI phylum, are loop-negative, as are the
mammalian b-glucuronidases. While closely related organisms
generally share similar loop phenotypes, this not a universal
feature of the tree. For example, within the Firmicutes (Figure S7,
blue branches), some loop-positive sequences cluster with loop-
negative sequences.Wealso find loop-positive fungal (FigureS7,
orange), archaeal Crenarchaeota, and even Euryarchaeota
b-glucuronidases (Figure S7, cyan and light blue, respectively),
in spite of the fact that the mammalian b-glucuronidases are
loop-negative. The presence is likely linked to the propensity
for organisms to utilize smaller glucuronides rather than larger
ones as sources of carbon that can be scavenged. However,
phylogenetic and biochemical analysis of Ascomycete fungi
suggested previously that the b-glucuronidase gene was hori-
zontally transferred from bacteria, potentially enabling fungi to
make use of glucuronic acids as a carbon source in the context
of a vertebrate host (Wenzl et al., 2005).
We find that the presence of the active-site loop confers sensi-
tivity to inhibition. We demonstrate that the NL b-glucuronidase
from B. fragilis (BfGUS) is inhibited neither by the eight microbial
b-glucuronidase inhibitors reported previously (Wallace et al.,
2010; Roberts et al., 2013) nor by Inhibitors R1 and R3 presented
here. It was previously shown that deleting the loop from EcGUS
creates an enzyme that retains activity but is no longer subject to
inhibition (Wallace et al., 2010). Together, these results define a1246 Chemistry & Biology 22, 1238–1249, September 17, 2015 ª201crucial functional difference between L and NL b-glucuroni-
dases. We predict that NL-GUS enzymes will be unable to utilize
glucuronide conjugates such as SN-38-G as well as the L-GUS
enzymes, as NL-GUSproteins lack the active-site loop predicted
to be necessary to close over these molecules. By contrast,
L-GUS enzymes have been shown to utilize small glucuronides
such as SN-38-G and diclofenac-G as substrates (Wallace
et al., 2010; Roberts et al., 2013). Thus, the ability to selectively
inhibit L-GUS enzymes over their NL-GUS counterparts appears
particularly useful in the prevention of drug-induced GI toxicity.
We hypothesized that limiting the serum exposure of inhibitors
would be beneficial to their efficacy, as such compounds would
potentially spend more time in the GI tract. The designed Inhib-
itor 1 analog R1 did show reduced serum exposure after oral
dosing in mice. However, it was found to be less efficacious
than Inhibitor 1 in alleviating diarrhea. There may be several
explanations for this result. First, R1 shows reduced potency
against EcGUS, and complete lack of inhibition of SaGUS or
CpGUS. Thus, it is relatively weak as an inhibitor in vitro, which
may correspond to weak efficacy in vivo. Second, the reduction
of Inhibitor R1 levels in the plasma could be caused by its rapid
metabolism and elimination and not by its reduced absorption
from the GI tract. Examination of intestinal contents for intact
inhibitors, and detailed inhibitor metabolism studies, will be
required to understand the pharmacokinetics and pharmacody-
namics of the microbiota-targeted compounds in vivo.
Importantly, we find that inhibition of microbial GI b-glucuron-
idases does not alter the serum levels of CPT-11 and its key
metabolites in mice. Controversy has existed over the route by
which SN-38, the active metabolite of CPT-11, reaches colon
tumors. Particularly, it is not clear whether the reabsorption of
SN-38 reactivated by the GI microbiota from the GI lumen plays
a significant role in colon tumor exposure, and subsequent effi-
cacy. Recent data using transgenic mice have suggested that,
like most chemotherapies, SN-38 delivery to the tumors would
be expected to occur through the systemic vasculature (Chen
et al., 2013). Furthermore, SN-38 produced in the GI lumen is5 Elsevier Ltd All rights reserved
subject to epithelial metabolism back to SN-38-G and export
back to the lumen (Chen et al., 2013). The data presented here
support the conclusion that reabsorption of reactivated SN-38
from theGI tract does not play a role in plasma levels of this com-
pound, CPT-11, or SN-38-G. We therefore hypothesize that
inhibition of GI bacterial b-glucuronidases would not negatively
affect tumor response to CPT-11. Recent data from another
group validates this hypothesis and demonstrates that Inhibitor
1 and other b-glucuronidase inhibitors improve tumor regression
in mice receiving CPT-11 (Kong et al., 2014). Thus, by reducing
the GI side effects of CPT-11, bacterial b-glucuronidase inhibi-
tors might also improve outcomes in human patients receiving
CPT-11 as part of the FOLFIRI or FOLFIRINOX regimen for colon
and pancreas cancers, respectively.
SIGNIFICANCE
Conjugating glucuronic acid to chemicals marked for
excretion is fundamental to xenobiotic and endobioticmeta-
bolism. Glucuronide conjugates are reactivated by glucuro-
nide-scavenging b-glucuronidases in the GI microbiota, and
such reactivated compounds can significantly damage the
GI tract. This effect has been established for the chemo-
therapeutic irinotecan and for NSAIDs. Selective, potent,
and non-lethal inhibition of bacterial b-glucuronidases was
recently shown to alleviate drug-induced GI damage. Here
we elucidate the structure and function of b-glucuronidases
from the mammalian GI microbial phyla Firmicutes and Bac-
teroidetes. We show that b-glucuronidases exhibit marked
differences in their catalytic activities and propensities
for inhibition, and that small changes in inhibitor structure
can alter b-glucuronidase active-site conformation. A phy-
logeny of extant b-glucuronidases establishes two major
enzyme clusters: L-GUS enzymes with active-site loops,
and NL-GUS enzymes without loops. GI bacterial b-glucu-
ronidase inhibition in mice does not alter the serum phar-
macokinetics of irinotecan, its active metabolite SN-38, or
its inactive glucuronide SN-38-G. Furthermore, reducing
inhibitor serum exposure does not enhance alleviation of
drug-induced GI toxicity, suggesting that increasing GI resi-
dence of inhibitors is not essential to efficacy. Finally, unlike
the Proteobacteria and Firmicutes enzymes, the B. fragilis
b-glucuronidase is not subject to inhibition by our selective
reagents. Together, these data advance our understanding
of the structure, function, and inhibition of the microbial
b-glucuronidases, a promising set of new therapeutic drug
targets for controlling drug-induced GI toxicity and the first
targets identified in the microbiome.
EXPERIMENTAL PROCEDURES
Protein Purification, Crystallization, and Structure Determination
Genomic DNA was derived from S. agalactiae 2603V/R (ATCC #BAA-611D-5),
and was graciously provided by Dr. Bruce McClane (University of Pittsburgh
School of Medicine) for C. perfringens str. 13. Enzymes were cloned by PCR
into pLIC-His (S. agalactiae) and pLIC-MBP (C. perfringens) ligation inde-
pendent cloning (LIC) vectors. The pLIC-His vector contains an N-terminal
6x-histidine tag, and the pLIC-MBP plasmid incorporates an N-terminal
MBP-fusion and 6x-histidine tag. Proteins were expressed in E. coli BL21-
DE3 AI competent cells (Invitrogen) and purified by column chromatography.Chemistry & Biology 22, 1238–124Similar methods were employed for BfGUS. His-SaGUS crystals were opti-
mized for quality in 0.1–0.3 M potassium thiocyanate and 20%–28% polyeth-
ylene glycol (PEG) 3350 at 16C. Crystals of MBP-CpGUS were grown at 16C
in 0.1M 2-(N-morpholino)ethanesulfonic acid (pH 6.0–6.5) and 28%–36%PEG
400. The E. coli b-glucuronidase (EcGUS)-R1 complex crystals were obtained
as first described by Wallace et al. (2010) with modifications for co-crystal-
lization as described by Roberts et al. (2013). Crystals were flash-frozen in
liquid nitrogen in preparation for X-ray data collection. Diffraction data were
collected on the 23-ID beamline at GM/CA-CAT (Advanced Photon Source,
Argonne National Laboratory). Data were processed using standard methods
and structures determined by molecular replacement using the EcGUS struc-
ture as a search model (PDB: 3K46). Structures were refined using standard
methods. See Supplemental Information for more details. Coordinates and
structure factors can be found at PDB: 4JKM, 4JKK, 4JKL, 5CZK.
Enzyme Assays
Assays were performed using the His-SaGUS, MBP-CpGUS, BfGUS, and
His-EcGUS enzymes. Kinetic assays used p-nitrophenyl glucuronide as the
absorbance substrate. Reactions were conducted in 96-well, clear-bottom
assay plates (Costar) at 37C in a 50-ml total volume. The reaction was per-
formed at 37C and product formation was measured using a PHERAstar
Plus microplate reader (BMG Labtech). Initial velocities were determined for
multiple substrate and enzyme concentrations, andMichaelis-Menten kinetics
were used to calculate KM, kcat, and catalytic efficiency. Inhibition assays were
performed using the same enzymes to assess the efficiency of Inhibitors 1–8,
R1, and R3 to disrupt enzymatic activity from various bacterial species.
Cell-based assays to calculate EC50 were performed as described by Roberts
et al. (2013) and Wallace et al. (2010). High-performance liquid chromatog-
raphy (HPLC) assays of SN-38-G (Santa Cruz Biotechnology) conversion to
SN-38 (Santa Cruz) were conducted as described by Wallace et al. (2010).
Structures were refined using standard methods. See Supplemental Informa-
tion for more details.
CPT-11 and Inhibitor Studies in Mice
Animal experiments were performed according to the Institutional Animal
Care and Use guidelines approved by the Institutional Animal Care and Use
Committee (IACUC nos. 20070715 and 20100711) of the Albert Einstein Col-
lege of Medicine, Bronx, NY.
Alleviation of CPT-11-induced toxicity studies were performed as described
previously (Roberts et al., 2013). Inhibitor R1 and R3 pharmacokinetic analyses
were performed identically to those described previously (LoGuidice et al.,
2012). CPT-11, SN-38, and SN-38-G pharmacokinetic analysis was performed
as follows. CPT-11 was administered at 50mg/kg i.p.3 1with or without 20 mg
of Inhibitor 1 per day (oral gavage of 10 mg twice daily for 3 days prior to CPT-11
administration and once at CPT-11 administration) in Balb/cJ wild-type
mice. Analytes were separated using a Shimadzu LC-20 HPLC instrument
equipped with a Waters XBridge C18 column (2.5 mm, 2.1 3 50 mm). Quanti-
tative analysis was performed by a Thermo Exactive Orbitrap mass spec-
trometer equipped with a heated electrospray ionization source, operating in
positive mode with enhanced resolution and optimized for high dynamic
range. Structures were refined using standard methods. See Supplemental
Information for more details.
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